Showing 4671-4680 of 8205 results for "".
- Cynosure Taps Consumer Products Vet Anne Gates for Its Board of Directorshttps://practicaldermatology.com/news/cynosure-taps-consumer-products-veteran-anne-gates-for-its-board-of-directors/2460525/Anne Gates, former President at MGA Entertainment and Executive Vice President and CFO of The Walt Disney Company's Consumer Products Division, has joined Cynosure’s board of directors and will chair the company's audit committee. "Anne brings with her a wealth o
- Dr. Doris Day Joins Nufabrx’s Ad Boardhttps://practicaldermatology.com/news/dr-doris-day-joins-nufabrxs-ad-board/2460523/New York City dermatologist Doris Day, MD is the newest member of Nufabrx’s advisory board. Nufabrx is an advanced textiles company that has developed a proprietary biomaterial platform that embeds active ingredients into fabrics to 
- Remembering 9-11: A Dermatology Perspectivehttps://practicaldermatology.com/news/remembering-9-11-a-dermatology-perspective/2460522/New research takes a close look at dermatologic injuries and chronic skin conditions that have affected survivors and responders during the nearly two decades since the terrorist attacks on September 11, 2001. These chronic illnesses include sarcoidosis, autoimmune disease, ill-defined
- ICYMI: ASA Honors Drs. Doris Day and Mark Lebwohl at Virtual Galahttps://practicaldermatology.com/news/icymi-asa-honors-drs-doris-day-and-mark-lebwohl-at-virtual-gala/2460521/Dermatologists Drs. Doris Day and Mark Lebwohl took home top awards at the American Skin Association’s (ASA) annual gala, which was held virtually this year. Dr. Day, a clinical associate professor of dermatology at NYU Langone Medical Center, received ASA's Excellen
- Arcutis to Accelerate Program for ARQ-151 for Atopic Dermatitishttps://practicaldermatology.com/news/arcutis-to-accelerate-program-for-arq-151-for-atopic-dermatitis/2460520/Arcutis Biotherapeutics, Inc. plans to advance its program to develop ARQ-151 (topical roflumilast cream) for the treatment of atopic dermatitis into Phase 3 clinical trials without conducting the previously planned Phase 2b atopic dermatitis trial. The decision follows an End
- Medicine X Launches Eczema Xplained Patient Story To Drive Understanding and Awareness of ADhttps://practicaldermatology.com/news/medicine-x-launches-eczema-xplained-patient-story-to-drive-understanding-and-awareness-of-ad/2460519/Medicine X today is launching Eczema Xplained, its first illustrated story in the U.S. on atopic dermatitis, the most comm
- Keystone Dermatology Virtual CME Conference Coming October 8-10https://practicaldermatology.com/news/keystone-dermatology-virtual-cme-conference-coming-october-8-10/2460517/Pennsylvania Dermatology Physician Assistants has transitioned its annual meeting to a virtual format. Registration is now open for Keystone Dermatology Virtual CME Conference, to be held October 8-10, 2020. Early bird registration ends September 8. Topics to be
- Arena Pharmaceuticals Announces First Subject Dosed in Phase 2 Trial Evaluating Etrasimod in Alopecia Areatahttps://practicaldermatology.com/news/arena-pharmaceuticals-announces-first-subject-dosed-in-phase-2-trial-evaluating-etrasimod-in-alopecia-areata/2460515/The first subject has been dosed in
- Revance Commercial Infrastructure to Launch RHA Collection of Dermal Fillershttps://practicaldermatology.com/news/revance-commercial-infrastructure-to-launch-rha-collection-of-dermal-fillers/2460512/Revance Therapeutics, Inc. will begin introducing the RHA Collection of dermal fillers, Resilient Hyaluronic Acid, and the HintMD financial technology platform, in the United States in September. The RHA Collection of derma
- Positive Phase 3 Results for Dermavant's Tapinarof Cream for Plaque Psoriasishttps://practicaldermatology.com/news/positive-phase-3-results-results-for-dermavants-tapinarof-cream-for-plaque-psoriasis/2460511/Dermavant Sciences shared positive results from PSOARING 1 and PSOARING 2, two identical, multi-center, randomized, vehicle-controlled, double-blind, parallel studies to evaluate the efficacy and safety of tapinarof cream 1% in adult patients with plaque psoriasis. In both PSOARING 1 (N